Amylyx Pharmaceuticals vs Eton Pharmaceuticals
AMLX and ETON side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMLX and ETON compare
Amylyx Pharmaceuticals is the larger company, worth 1.8 times as much as Eton Pharmaceuticals ($3.4B against $1.8B).
Eton Pharmaceuticals scores higher on the StockData Score (12 against 7 for Amylyx Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMLX | ETON |
|---|---|---|
| Size and price | ||
| Market cap | $3.4B | $1.8B |
| Share price | $30.29 | $63.93 |
| Change, 1 year | 146% | 266% |
| Change, 5 years | 182% | 1302% |
| Beta (5Y) | 1.15 | 0.88 |
| Employees | 136 | 44 |
| StockData Score | ||
| Total score | 7 | 12 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 4 (better) |
| Performance score | 1 | 4 (better) |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 42.1× |
| P/S | – | 13.0× |
| P/B | 4.5× (better) | 21.0× |
| EV/EBITDA | – | 39.3× |
| P/FCF | – | 47.8× |
| FCF yield | – | 2.1% |
| Fair value | – | $33.76 |
| Margin of safety | – | −89.4% |
| Growth | ||
| Revenue growth (TTM) | – | 101% |
| Revenue growth, 5Y average | – | 360% |
| Profitability | ||
| Gross margin | – | 69.2% |
| Operating margin | – | 28.8% |
| Net margin | – | 35.3% |
| FCF margin | – | 27.1% |
| Return on equity | −30.1% | 90.6% (better) |
| Return on invested capital | – | 115% |
| Financial health | ||
| Debt / equity | 0.00 | 0.27 (better) |
| Net debt / EBITDA | – | −0.71 |
| Current ratio | 26.81 (better) | 1.79 |
| Altman Z-score | 60.09 (better) | 17.09 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 104% | 74.0% |
| Held by insiders | 7.8% | 5.6% |
| Insider net buying, 12 months | −$17.2M (better) | −$35.0M |
| Short interest, % of float | 12.5% | 7.4% |
Go deeper
- AMLX stock overview
- AMLX income statement
- AMLX valuation and score
- ETON stock overview
- ETON income statement
- ETON valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.